ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
14.01
-0.10 (-0.71%)
At close: Nov 15, 2024, 4:00 PM
13.79
-0.22 (-1.57%)
After-hours: Nov 15, 2024, 5:08 PM EST
ARS Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Cash & Equivalents | 39.66 | 70.97 | 210.52 | 60.06 | 24.52 |
| Short-Term Investments | 165.16 | 157.39 | 63.86 | - | - |
| Cash & Short-Term Investments | 204.82 | 228.36 | 274.38 | 60.06 | 24.52 |
| Cash Growth | -15.33% | -16.77% | 356.82% | 144.95% | - |
| Accounts Receivable | 0.77 | - | - | - | 0.38 |
| Other Receivables | 0.47 | 0.8 | 1.01 | 0 | 0 |
| Receivables | 1.24 | 0.8 | 1.01 | 0 | 0.38 |
| Prepaid Expenses | 1.29 | 2.03 | 2.31 | 0.67 | 1.48 |
| Other Current Assets | 0.73 | 0.54 | - | - | - |
| Total Current Assets | 208.79 | 231.73 | 277.7 | 60.73 | 26.38 |
| Property, Plant & Equipment | 0.94 | 0.82 | 0.77 | 0.69 | 0.02 |
| Long-Term Deferred Charges | 0.38 | 0.62 | - | - | - |
| Other Long-Term Assets | - | 0.02 | 2.96 | 0.02 | 0 |
| Total Assets | 217.6 | 233.19 | 281.44 | 61.45 | 26.41 |
| Accounts Payable | 8.28 | 0.76 | 1.66 | 1.79 | 1.22 |
| Accrued Expenses | 7.04 | 1.24 | 2.1 | 1.3 | 0.84 |
| Current Portion of Long-Term Debt | - | - | - | 3.48 | 2.56 |
| Current Portion of Leases | 0.1 | 0.24 | 0.23 | 0.14 | - |
| Current Income Taxes Payable | - | 0 | 0.17 | - | - |
| Current Unearned Revenue | - | - | 0.28 | 1.46 | 3.52 |
| Other Current Liabilities | 1.2 | 0.16 | 1 | 0.02 | 0.08 |
| Total Current Liabilities | 16.62 | 2.39 | 5.44 | 8.19 | 8.21 |
| Long-Term Debt | - | - | - | 4.93 | 7.46 |
| Long-Term Leases | - | 0.04 | 0.25 | 0.48 | - |
| Long-Term Unearned Revenue | - | - | 2.85 | 3 | 3.44 |
| Other Long-Term Liabilities | - | - | - | 0.08 | 0.11 |
| Total Liabilities | 16.62 | 2.43 | 8.55 | 16.68 | 19.23 |
| Common Stock | 0.01 | 0.01 | 0.01 | 0 | 0.22 |
| Additional Paid-In Capital | 373.87 | 362 | 349.41 | 10.98 | 7.74 |
| Retained Earnings | -173.24 | -131.3 | -76.94 | -42.26 | -22.01 |
| Comprehensive Income & Other | 0.34 | 0.05 | 0.41 | - | - |
| Total Common Equity | 200.98 | 230.76 | 272.89 | -31.27 | -14.05 |
| Shareholders' Equity | 200.98 | 230.76 | 272.89 | 44.77 | 7.18 |
| Total Liabilities & Equity | 217.6 | 233.19 | 281.44 | 61.45 | 26.41 |
| Total Debt | 0.1 | 0.27 | 0.48 | 9.03 | 10.02 |
| Net Cash (Debt) | 204.71 | 228.09 | 273.9 | 51.03 | 14.5 |
| Net Cash Growth | -15.26% | -16.73% | 436.74% | 251.86% | - |
| Net Cash Per Share | 2.12 | 2.40 | 6.86 | 1.77 | 0.72 |
| Filing Date Shares Outstanding | 97.19 | 96.5 | 94.4 | 25.7 | 20.22 |
| Total Common Shares Outstanding | 97.15 | 96.41 | 93.94 | 25.7 | 20.22 |
| Working Capital | 192.17 | 229.34 | 272.26 | 52.54 | 18.17 |
| Book Value Per Share | 2.07 | 2.39 | 2.90 | -1.22 | -0.70 |
| Tangible Book Value | 193.48 | 230.76 | 272.89 | -31.27 | -14.05 |
| Tangible Book Value Per Share | 1.99 | 2.39 | 2.90 | -1.22 | -0.70 |
| Machinery | 0.99 | 0.7 | 0.38 | 0.09 | 0.03 |
Source: S&P Capital IQ. Standard template. Financial Sources.